Skip to main content
. Author manuscript; available in PMC: 2021 Mar 25.
Published in final edited form as: Fatigue. 2021 Feb 2;8(4):226–244. doi: 10.1080/21641846.2021.1876613

Figure 4. Assessment of synergistic risks for CFS.

Figure 4.

Synergy was evaluated for low CD16A NK effector cell counts combined with low ADCC capacities. CFS family members, with CFS and without CFS, were compared to unrelated controls. Division of the quadrants was based on the median values of each variable. A. CX1:1. Data are from families #3, 10 & 28. B. CX-slopes. Data are from families #3, 10, 22 & 28. Ps <0.05 for family members in the low-low quadrants.